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ABSTRACT
The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) commenced collecting data on
hematopoietic stem cell transplantation (HSCT) in 1992, and by 2004 had accrued more than 12,000 transplant
records from 44 centers. In 2004 the Australian annual per capita autograft activity rate was almost twice that
of New Zealand (381 per 10 million compared to 195), whereas the 2 countries had similar allografting activity
rates (Australia 145, New Zealand 133). The annual rates of allogeneic HSCT per 10 million population in
Australia and New Zealand in 2004 were similar to those in European countries of comparable socioeconomic
status. Among the most prominent trends between 1998 and 2004 were increases in the numbers of allogeneic
HSCT using peripheral blood stem cells (PBSC), the emergence of reduced intensity conditioning in alloge-
neic HSCT, increases in numbers of autologous HSCT for recipients aged 60 and over, increases in allogeneic
HSCT with unrelated donors, and decreases in numbers of allogeneic HSCT for chronic myelogenous
leukemia and autologous HSCT for breast cancer. The cumulative incidence of transplant-related mortality
(TRM) at 100 days posttransplant progressively fell over the years 1992 to 2003 and was 8.1% for allogeneic
HSCT and 1.1% for autologous HSCT in 2003. The ABMTRR is a valuable data resource providing timely and
accurate information on HSCT activity in Australia and New Zealand. Full enumeration of HSCT activity in
the 2 countries by the ABMTRR enhances its value in clinical planning and management.
© 2007 American Society for Blood and Marrow Transplantation
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1NTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
as been shown to induce long-term remissions and
ure for a proportion of patients with life-threatening
iseases, including acute and chronic leukemias, my-
lodysplastic syndromes, lymphomas, multiple my-
loma, aplastic anemia, immune disorders, and other
ongenital disorders of metabolism [1].
Data on HSCT activity and outcome is collected
y national and international clinical registries. The
enter for International Blood and Marrow Trans-
lant Research (CIBMTR) collects allogeneic HSCT
ata from over 400 participating centers worldwide
2]. The European Group for Blood and Marrow transplantation (EBMT) collects HSCT data from
ore than 600 centers in Europe [3] and captures an
stimated 90% of activity in these countries [4]. The
BMT also runs an annual Activity Survey [3]. Na-
ional HSCT registries also operate in many countries
ncluding Austria [5], Britain [6], Germany [7], Japan
8], The Netherlands [9], and Switzerland [10].
The Australasian (ie, Australian and New Zea-
and) Bone Marrow Transplant Recipient Registry
ABMTRR) commenced collecting data on HSCT
ustralia-wide in 1992 [11]. Transplant centers in
ew Zealand have contributed to the Registry since
998. By 2004, the ABMTRR had accrued more than
2,000 transplant records from 44 participating cen-
ers. Ownership of ABMTRR data is shared by the
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I. Nivison-Smith et al.906ontributing centers, which are collectively repre-
ented by the Bone Marrow Transplant Society of
ustralia and New Zealand (BMTSANZ).
This report describes HSCT activity in Australia
nd New Zealand during the years 1998 to 2004,
ighlighting current trends in transplant practice and
omparisons with worldwide activity recorded by in-
ernational registries.
ATERIALS AND METHODS
Every hospital in Australia and New Zealand that
arries out HSCT contributes data to the ABMTRR.
o remuneration is offered for participating in this
ata collection.
Each treating center seeks consent from consecu-
ive patients for their clinical data to be transferred to
he Registry. A single registration form is completed
t each center and sent to the Registry ofﬁce when a
ransplant is performed. This contains the following
nformation: coded patient and hospital identiﬁcation,
tate and postcode of usual residence, sex, age, date of
irth, transplant date, type of transplant, stem cell
ource, type of stem cell mobilization, allogeneic do-
or details, disease diagnosis, and status at time of
ransplant.
The ABMTRR aims for full enumeration of
SCT in Australasia each year so that data can be
sed for administrative as well as research purposes.
he list of corresponding hospitals is assessed for
ompleteness on a regular basis via correspondence
ith leading transplant physicians. At the commence-
ent of each calendar year there is a phase of fol-
ow-up where each hospital is contacted to ensure they
ave supplied all of the previous year registrations. In
he year 2001 it was estimated that 99.5% of all
SCT activity in the 2 countries was captured by the
egistry [11].
An annual follow-up request is sent from the Reg-
stry to each contributing center, listing HSCT recip-
Figure 1. HSCT activity by type, Australia, 1998-2004.ents who are recorded as alive. The request asks forummary information on graft failure, persistent dis-
ase, relapse, new malignancy, death, and cause of
eath.
Within 12 months of the completion of a calendar
ear, an Annual Data Summary showing summary
esults of activity and outcome is distributed to par-
icipating centers and interested researchers.
Calculations of HSCT per 10 million population
n 2004 used Estimated Resident Population ﬁgures
or June 30, 2004, produced by the Australian Bureau
f Statistics [12] and Statistics New Zealand [13].
Transplant-related mortality (TRM) is deﬁned
ere as deaths in the ﬁrst 100 days posttransplant from
ransplant-related causes. TRM was calculated by the
ethod of cumulative incidence considering relapse,
ersistence, or progression of the original disease as
ompeting risks [14,15]. Staged autologous trans-
lants are planned multiple autologous transplants in-
luding tandem transplants.
ESULTS
In 2004, a total of 808 autologous, 203 allogeneic-
elated donor, and 157 allogeneic-unrelated donor
SCT were performed in Australia, whereas in New
ealand the corresponding numbers were 81, 48, and 16.
Figures 1 and 2 show numbers of HSCT in the 2
ountries in recent years, indicating steady activity
ver the years 1998 to 2001 and gradual increases over
he years 2002 to 2004.
The number of ﬁrst HSCT in Australia in 2004
quated to 145 allografts and 381 autografts per 10
illion population. For New Zealand the correspond-
ng rates were 133 and 195, respectively. Table 1
hows Australian and New Zealand annual per capita
ctivity compared to European countries as described
n the EBMT Activity Survey [4].
In Australia in 2004, autologous procedures rep-
esented 70% of all HSCT activity, whereas in New
ealand they represented 56%. Of 808 autologousFigure 2. HSCT activity by type, New Zealand, 1998-2004.
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HSCT Activity in Australia and New Zealand 1992-2004 907rocedures performed in Australia, 63 or 7.8% were
arried out in 2 or more stages, whereas in New
ealand, no staged autologous HSCT were per-
ormed. The age range for autologous HSCT was 8
onths to 78 years in Australia and 3 to 66 years in
ew Zealand. The major indications for autologous
SCT in Australia were non-Hodgkin’s lymphoma
NHL) (300, 37%) and myeloma (309, 38%). These 2
ndications also had the largest numbers in New Zea-
and (NHL 32, 40%, myeloma 37, 46%).
Table 2 displays transplant numbers in 2004 ac-
ording to indication. For autologous HSCT (single
r staged), the major indications were NHL, multiple
yeloma, and Hodgkin’s lymphoma, accounting for
able 1. Hematopoietic Stem Cell Transplants per 10 Million Populati
ountries
Allogeneic
Range Countries
>150 Belgium, Finland, Germany, Italy, Netherlands,
Sweden
101-150 Australia, Austria, Croatia, Czech Republic,
Denmark, France, Ireland, New Zealand,
Spain, Switzerland, UK
51-100 Greece, Norway, Poland, Portugal
1-50 Belarus, Bulgaria, Estonia, Hungary, Lithuania,
Macedonia, Romania, Russia, Turkey, Ukraine
able 2. Indication for HSCT by Recipient Age at Transplant, Austral
Allogeneic,
Related Donor
Age (years)
Indication 0-14 15
LL in CR1 5 5
LL not in CR1 5 10
ML in CR1 8 50
ML not in CR1 8 44
ML in CP1 1 10
ML not in CP1 0 9
myloidosis 0 0
hronic myelofibrosis 0 6
LL 0 6
wing sarcoma 0 1
odgkin lymphoma 1 7
edulloblastoma 0 0
ultiple myeloma 0 15
yelodysplastic syndrome 1 3
euroblastoma 0 0
on-Hodgkin lymphoma 1 28
NET 0 0
habdomyosarcoma 0 0
AA 2 9
esticular carcinoma 0 0
ther indications 4 12
otal 36 215
umbers in table include ﬁrst, second, and subsequent HSCT.
LL indicates acute lymphoblastic leukemia; AML, acute myelog
myelogenous leukemia; CP1, ﬁrst chronic phase; CR1, ﬁrst c
non-Hodgkin’s lymphoma; PNET, primitive neuro-ectodermal tumor3% of total autologous activity. For allogeneic
SCT with related donors, largest numbers were
erformed for acute myelogenous leukemia (AML),
HL, multiple myeloma, and acute lymphoblastic
eukemia (ALL) (71% of total allogeneic related donor
SCT). For allogeneic HSCT with volunteer unre-
ated donors, the major indications were AML, NHL,
nd ALL (68% of total allogeneic-unrelated donor
SCT). Table 3 shows numbers of HSCT for major
ndications by country.
Table 4 shows ﬁrst transplants for major indica-
ions as a proportion of total activity, again compared
ith ﬁgures from European centers compiled by the
BMT [4]. The relative proportions of speciﬁc
4: Australia and New Zealand Compared to Selected European
Autologous
Range Countries
>300 Australia, Belgium, Denmark, Finland, France,
Italy, Netherlands, Spain, Sweden
151-300 Austria, Croatia, Czech Republic, Germany,
Greece, Ireland, New Zealand, Norway,
Portugal, Switzerland, UK
51-150 Macedonia, Poland
1-50 Belarus, Bulgaria, Estonia, Hungary, Lithuania,
Romania, Russia, Turkey, Ukraine
ew Zealand, 2004
Allogeneic,
nrelated Donor
Age (years)
Autologous
Age (years)
4 15 0-14 15 Total
13 0 4 30
17 0 5 49
14 4 13 92
32 0 10 102
7 0 0 18
4 0 5 20
0 0 23 23
1 0 0 7
3 0 4 13
0 6 3 10
4 1 61 74
0 8 0 8
5 0 346 366
7 0 1 12
0 13 1 14
15 3 329 377
0 5 0 5
0 2 3 5
2 0 1 15
0 0 11 11
2 7 20 62
126 49 840 1,313
leukemia; CLL, chronic lymphoblastic leukemia; CML, chronic
e remission; HSCT, hematopoietic stem cell transplants; NHL,on, 200ia and N
U
0-1
3
12
3
8
0
2
0
0
0
0
0
0
0
0
0
1
0
0
1
0
17
47
enous
omplet; SCID, severe combined immune disorder.
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I. Nivison-Smith et al.908SCT indications are similar between the 2 databases
ith the exceptions of allografts for AML (43% of
otal allografts in Australasia, compared to 32% for
uropean countries) and autografts for NHL (38% in
ustralasia, compared to 30% for European coun-
ries).
Table 5 shows a time series of recent trends in
SCT in Australia and New Zealand. Among the
ost prominent of these are increases in the numbers
f allogeneic HSCT using peripheral blood stem cells
PBSC), the emergence of reduced intensity condi-
ioning (RIC) in allogeneic HSCT, steady increases in
umbers of autologous HSCT for recipients aged 60
nd over, and an increase in cord blood transplants
rom 2003. In 2003 and 2004, more than half of
able 3. Major Indication for Transplant by Transplant Type and Cou
Allogeneic,
Related Donor
Country
Indication Aust NZ
LL in CR1 10 0
LL not in CR1 12 3
ML in CR1 50 8
ML not in CR1 42 10
ML in CP1 8 3
ML not in CP1 8 1
myloidosis 0 0
odgkin lymphoma 8 0
ultiple myeloma 8 7
on-Hodgkin lymphoma 21 8
ther indications 36 8
otal 203 48
umbers in table include ﬁrst, second, and subsequent hematopoie
LL indicates acute lymphoblastic leukemia; AML, acute myelogen
remission; CP1, ﬁrst chronic phase.
able 4. First Hematopoietic Stem Cell Transplants (HSCT) for
ajor Indications as a Proportion of Total Activity: Comparison
etween ABMTRR and EBMT, 2004
Indicator ABMTRR EBMT
nrelated donor HSCT as a
proportion of total allografts 40% 38%
pecific indications as a proportion
of total allografts
AML 43% 32%
ALL 19% 19%
CML 8% 11%
NHL 9% 7%
SAA 4% 5%
pecific indications as a proportion
of total autografts
NHL 38% 30%
Myeloma 37% 36%
able calculated using numbers for ﬁrst HSCT only.
LL indicates acute lymphoblastic leukemia; AML, acute myelog-
enous leukemia; CML, chronic myelogenous leukemia; NHL,tnon-Hodgkin lymphoma.llogeneic HSCT with recipients aged up to 15 years
sed stem cells from unrelated donors.
Numbers of allogeneic HSCT for chronic my-
logenous leukemia (CML) in the ﬁrst chronic phase
ropped sharply in 2001 and have been relatively low
ince that time. Numbers of autologous HSCT for
reast cancer have decreased from 1999, and in 2004,
one were performed.
Figures 3 and 4 highlight long-term trends in
ustralia over the years 1992 to 2004. Unrelated vol-
nteers have increased strongly as stem cell donors
articularly in pediatric allogeneic HSCT (Figure 3).
RM up to 100 days posttransplant has declined
teadily for allogeneic HSCT, from 22% in 1992 to
% in 2003, and similarly for autologous HSCT, from
% to 1% (Figure 4).
Figures 5 and 6 show the cumulative incidence
RM curves for allogeneic and autoHSCT for the
ggregated years of 1992 to 1997 compared with 1998
o 2003, showing that TRM has signiﬁcantly de-
reased in the second time span.
ISCUSSION
Hematopoietic stem cell transplantation is a well
stablished clinical procedure around the world. The
nalysis here indicates that HSCT practice in Aus-
ralasia as measured by activity is broadly similar to
hat seen internationally.
Australian annual per capita autograft activity is
lmost twice that of New Zealand (381 per 10 million
ompared to 195 in 2004), whereas the 2 countries
ave similar allografting activity. The annual rates of
llogeneic HSCT per 10 million population in Aus-
ustralia and New Zealand, 2004
Allogeneic,
related Donor
Country
Autologous
Country
t NZ Aust NZ Total
1 3 1 30
2 5 0 49
2 17 0 92
4 10 0 102
0 0 0 18
0 5 0 20
0 23 0 23
0 55 7 74
0 309 37 366
1 300 32 377
6 81 4 162
16 808 81 1,313
cell transplants.
kemia; CML, chronic myelogenous leukemia; CR1, ﬁrst completentry, A
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HSCT Activity in Australia and New Zealand 1992-2004 909ries such as Denmark, France, and the United King-
om, but lower than Germany, Italy, and Sweden.
he current Australian autologous HSCT per capita
ate is comparable with countries such as France, Italy,
nd Sweden, whereas for New Zealand the rate is
imilar to Germany, Ireland, and the United King-
om. This indicates that HSCT rates are broadly
imilar across nations with comparable socioeconomic
tatus.
The data for 2004 show that the number of autol-
able 5. Trends in Therapies and Indications for HSCT, 1998-2004,
1998 19
ransplant type
Allogeneic related/syngeneic 269 277
Allogeneic unrelated 90 113
Autologous single 559 537
Autologous staged 176 122
Allo unrelated as % of allos: age 0-14 35% 40
Allo unrelated as % of allos: age 15 22% 26
ecipient age
Allogeneic recipients aged 50-59 51 66
Allogeneic recipients aged 60 3 6
Autologous recipients aged 60-69 92 93
Autologous recipients aged 70 7 11
ell source/conditioning/HLA match
Allogeneic HSCT using PBSC 147 172
Allogeneic HSCT using RIC nav 29
Allogeneic-related HSCT with >1 HLA
mismatch 7 10
Allo-unrelated HSCT using cord blood 12 11
ndication for transplant
Autologous HSCT for breast cancer 119 56
Autologous HSCT for myeloma 164 155
Autologous HSCT for NHL 224 205
Allogeneic HSCT for CML in CP1 15 66
Allogeneic HSCT for CML not in CP1 6 17
ransplant-related mortality
(Australia only)
TRM for autologous HSCT 3.3% 1
TRM for allogeneic HSCT 17.6% 14
BSC indicates peripheral blood stem cells; RIC, reduced intensity
myelogenous leukemia; CP1, ﬁrst chronic phase; HSCT, hema
transplant-related mortality.
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igure 3. Alternative (ie, other than HLA-identical sibling) donor
SCT as proportion of total allogeneic HSCT, Australia, 1992-
004. tgous procedures performed in New Zealand is lower
han would be expected when compared to Australia.
his appears to result from reduced usage of au-
ografting as a treatment modality, particularly for the
ajor indications of multiple myeloma and NHL. It
ay also reﬂect a more conservative attitude to-
ards autografting patients over the age of 65.
The most recent time trend in HSCT is a gradual
ncrease in total HSCT numbers since 2001 in the
rder of 7% per year. However, this overall growth
attern has been inﬂuenced by a number of factors
a and New Zealand
2000 2001 2002 2003 2004
293 263 268 245 251
113 101 134 164 173
551 618 741 775 825
63 60 60 69 64
59% 58% 52% 62% 57%
21% 22% 30% 35% 37%
83 88 79 97 103
22 16 16 16 15
121 137 192 214 253
8 19 24 29 32
231 226 265 276 300
40 66 91 126 130
2 2 3 2 6
14 18 12 31 33
15 6 7 3 0
189 210 290 338 346
223 248 291 300 332
56 27 27 11 18
17 20 21 20 15
1.8% 1.6% 2.2% 1.1% nya
13.6% 12.0% 12.4% 8.1% nya
tioning; Nav, not available; Nya, not yet available; CML, chronic
ic stem cell transplants; NHL, non-Hodgkin’s lymphoma; TRM,
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I. Nivison-Smith et al.910ncluding increases in the numbers of older patients
ndergoing HSCT and transplants with unrelated do-
ors, and decreases in numbers of HSCT for breast
ancer and CML.
Larger numbers of older patients have contributed
o increases in numbers of autografts for NHL and
ultiple myeloma. This trend reﬂects increased safety
f these procedures because of a number of factors
ncluding shorter time to engraftment associated with
se of cytokine-mobilized blood stem cells, and the
outine use of broad-spectrum anti-infective prophy-
axis [1].
The majority of autografts for breast cancer in
ustralia and New Zealand were undertaken within a
linical trial context. These trials closed to accrual at
bout the same time that international randomized
rials suggested that there was little survival advantage
or autologous HSCT in breast cancer [16-20].
The reduction in number of allogeneic transplants
or CML is a direct result of the introduction of
matinib mesylate (Glivec, Novartis, East Hanover,
J) for the treatment of this disease in 2000, and the
triking response rates obtained with this drug. This
as resulted in a deferral of transplantation in favor
f therapy with this compound for the majority of
ewly diagnosed patients [21,22]. However, the
umber of allogeneic HSCT for patients with CML
eyond CP1 has not altered substantially in the past
years.
In 1994, the ﬁrst allogeneic transplant utilizing
eripheral blood-derived hematopoietic stem cells was
erformed in Australia [11] and by 1998, 41% of
llogeneic HSCT utilized either blood stem cells or a
ombination of blood and marrow stem cells. The
ptake of this form of stem cells has been inﬂuenced
y results of several studies that have shown faster
ngraftment times using blood stem cells compared to
arrow in allogeneic HSCT. Peripheral blood is now
he preferred hematopoietic stem cell source in Aus-
ralia and New Zealand, with 71% of allogeneic
0%
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15%
20%
25%
0 20 40 60 80 10
Days post transplant
TR
M
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0
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P<0.001
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1998 - 2003
igure 5. Cumulative incidence of TRM to 100 days posttransplant
or allogeneic hematopoietic stem cell transplants performed in
992-1997 and 1998-2003.SCT utilizing this source in 2004 [23-25]. 1Since 1999, the number of allogeneic HSCT using
IC has increased rapidly. These procedures can be
sed to transplant candidates with signiﬁcant comor-
idities, or who are older than would usually be ad-
isable for an allograft [26-28].
Reduction in TRM in recent years reﬂects im-
rovements in posttransplant safety, more rapid en-
raftment with PBSC, better antifungal agents, and
ncreasing numbers of allogeneic HSCT using RIC.
The increase in numbers of allogeneic HSCT us-
ng unrelated donors reﬂects the greater availability of
onor marrow worldwide as a result of recruitment to
he Australian and overseas donor registries [1], the
ecognition that unrelated donor transplantation pro-
ides equivalent safety to related donor transplanta-
ion in some conditions such as CML, and the intro-
uction of RIC.
Hematopoietic stem cell transplant activity from
ear to year may also be strongly inﬂuenced by factors
ot studied here, including a demographic shift to-
ards an older population resulting in a larger number
f patients being eligible for HSCT [29-32]. Apart
rom clinical and population inﬂuences, overall num-
ers of HSCT may also be signiﬁcantly inﬂuenced by
udget considerations at individual centers [33-35].
The ABMTRR is a valuable data resource provid-
ng timely and accurate information on HSCT activity
nd curative effect in Australia and New Zealand. As
ith other national registries [5-10], ABMTRR data
ave been used to highlight trends in HSCT activity,
nd as a base for multicenter retrospective studies of
SCT practice and outcome.
The fact that the ABMTRR captures almost all
SCT activity in the 2 countries opens valuable pos-
ibilities for population-based research on hematologic
alignancies and their therapies. The complete cover-
ge of HSCT activity also ensures that ABMTRR pro-
ides accurate data for use in discussions between
he medical community and government funding
uthorities.
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igure 6. Cumulative incidence of TRM to 100 days posttransplant
or autologous hematopoietic stem cell transplants performed in
992-1997 and 1998-2003.
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